Arthritis CD19+ B Cells
About: Arthritis CD19+ B Cells are isolated from IRB-consented donors with clinically confirmed Arthritis. Ideal for investigating B cell-mediated autoantibody production and immune dysregulation in autoimmune arthritis.
Arthritis CD19+ B Cells for Autoimmune Research
Arthritis CD19+ B Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with Arthritis. These CD19+ B cells reflect disease-associated immune alterations and offer a critical resource for studying autoantibody production, B cell activation, and humoral immunity in the context of Arthritis.
Product Features
- Research Use Only (RUO), CD19+ enriched B cells
- Isolated from clinically diagnosed Arthritis donors
- High viability and enrichment
- Cryopreserved in CryoStor® CS10 media
- Processed within 24 hours of collection
- Ethically sourced with IRB approval and HIPAA compliance
De-identified Donor Data
- Confirmed diagnosis of Arthritis
- Demographics: age, sex assigned at birth, race/ethnicity
- Self-reported clinical history and medication use
Applications
- Investigation of B cell phenotypes and function in Arthritis
- Autoantibody and immune exhaustion studies
- Disease mechanism studies and biomarker identification
- Preclinical immunotherapy development
Compliance and Quality Assurance
- IRB-approved collection and 21 CFR Part 11-compliant e-consent
- Standardized processing and quality protocols
- HIPAA-compliant data handling
Ordering & Customization
Arthritis CD19+ B Cells are offered in standard or custom aliquot sizes. For regulatory documentation or international support, contact learnmore@sanguinebio.com.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
CD19+ B Cells
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
1 Answer
All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more here. https://sanguinebio.com/patient-reported-outcomes-pro-surveys-questionnaires/
Ask a Question
Need a custom CD19+ B Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.